Great Lakes Advisors LLC lessened its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 20.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 178,477 shares of the biopharmaceutical company’s stock after selling 46,132 shares during the period. Great Lakes Advisors LLC’s holdings in Amicus Therapeutics were worth $1,681,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of FOLD. Los Angeles Capital Management LLC increased its holdings in Amicus Therapeutics by 46.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,484 shares during the period. Tokio Marine Asset Management Co. Ltd. bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $113,000. Wrapmanager Inc. bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $220,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Amicus Therapeutics by 51.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock worth $2,381,000 after acquiring an additional 75,807 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $834,000.
Amicus Therapeutics Price Performance
Shares of Amicus Therapeutics stock opened at $8.90 on Friday. Amicus Therapeutics, Inc. has a 52-week low of $8.55 and a 52-week high of $12.65. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -49.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a fifty day moving average of $9.38 and a 200-day moving average of $10.15. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on FOLD
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Read More
- Five stocks we like better than Amicus Therapeutics
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is a Secondary Public Offering? What Investors Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is a Stock Market Index and How Do You Use Them?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.